Accelerating Protein Therapy Development: Sartorius and LFB BIOMANUFACTURING Join Forces

Vantage Market Research

Jun 24, 2024

According to analysts at Vantage Market Research, the market for Next-Generation Biomanufacturing is projected to reach USD 39.4 billion by 2032, with a compound annual growth rate of 7.5%. In a strategic move aimed at revolutionizing the biopharmaceutical landscape, Sartorius and LFB BIOMANUFACTURING have forged a groundbreaking collaboration. Under this agreement, LFB BIOMANUFACTURING, an esteemed expert in therapeutic protein biomanufacturing, will entrust Sartorius with its cell line development (CLD) services. This partnership heralds a new era in biomanufacturing, offering customers seamless solutions to expedite protein therapy development.

Sartorius and LFB BIOMANUFACTURING intend to provide a full range of services, ranging from CLD to clinical production in combination with their respective strengths. This cooperation is a paradigm shift in the sector and provides customers with an integrated solution for accelerating their projects into production.

Navigating the complexities of biopharmaceutical development demands expertise & efficiency. Recognizing this need, the collaboration between Sartorius and LFB BIOMANUFACTURING seeks to streamline processes, alleviating the logistical and administrative burdens faced by developers. Through integrated timelines and state-of-the-art technologies, the partnership aims to simplify the drug development journey for clients.

A common commitment to innovation & client success is at the heart of this partnership. This collaboration promises to accelerate the development and commercialization of biologics through the use of Sartorius' high performing cell lines and media with LFB BIOMANUFACTURING's robust production platform. This synergy is intended to ensure that patients in the world have immediate access to life changing therapies.

With Sartorius spearheading CLD services, the collaboration is poised to expedite time-to-clinic and time-to-market for therapeutic molecules. As the partnership develops, it has the potential to transform the biomanufacturing landscape and lead to advances that benefit both patients and stakeholders.

In conclusion, the collaboration between Sartorius and LFB BIOMANUFACTURING represents an important step towards faster protein therapy development. The partners aim to bring about a new era of innovation and accessibility in biopharma through the merger of expertise, technology and vision.

Next-gen Biomanufacturing Market Size, Share & Trends Analysis Report by Workflow Type (Continuous Upstream Biomanufacturing Workflow, Single-Use Upstream Biomanufacturing Workflow, Downstream Biomanufacturing Workflow) by Application (Monoclonal Antibodies, Vaccines, Hormones, Recombinant Proteins, Other Applications) by End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Assessment (2018 - 2023) & Forecast (2024 - 2032)